Single domain antibody-scFv conjugate targeting amyloid β and TfR penetrates the blood-brain barrier and interacts with amyloid β
Neurodegenerative diseases such as Alzheimer's disease (AD) pose substantial challenges to patients and health-care systems, particularly in countries with aging populations. Immunotherapies, including the marketed antibodies lecanemab (Leqembi®) and donanemab (KisunlaTM), offer promise but fac...
Sparad:
Huvudskapare: | , , , , , , |
---|---|
Materialtyp: | Bok |
Publicerad: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Ämnen: | |
Länkar: | Connect to this object online. |
Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Internet
Connect to this object online.3rd Floor Main Library
Signum: |
A1234.567 |
---|---|
Exemplar 1 | Tillgänglig |